HOUSTON, May 8, 2024
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
("Moleculin" or the "Company"), a clinical stage pharmaceutical
company with a broad portfolio of drug candidates targeting
hard-to-treat tumors and viruses, today announced that it will
report its financial results for the quarter ended March 31, 2024, on Friday,
May 10, 2024. Moleculin management will host a conference
call and live audio webcast to discuss the operational and
financial results at 8:30 AM ET on Monday,
May 13, 2024.
Interested participants and investors may access the conference
call by dialing (877) 407-0832 (domestic) or (201) 689-8433
(international) and referencing the Moleculin Biotech Conference
Call. The live audio webcast will be accessible on the
Events page of the Investors section of the Moleculin
website, moleculin.com, and will be archived for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company
with a growing pipeline, including Phase 2 clinical programs, for
hard-to-treat tumors and viruses. The Company's lead program,
Annamycin is a next-generation anthracycline designed to avoid
multidrug resistance mechanisms with little to no cardiotoxicity.
Annamycin is currently in development for the treatment of relapsed
or refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases. All interim and preliminary data discussed
above is subject to change.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-report-first-quarter-2024-financial-results-on-may-10-2024-and-host-conference-call-and-webcast-302138835.html
SOURCE Moleculin Biotech, Inc.